BioSpace News Archive

Cybrexa Therapeutics announced the appointments of Laurie Kenvin as Vice President of Clinical Operations and Nick Saccomano, Ph.D., to the Company’s Scientific Advisory Board.

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today provided an update on the Twirla® post-marketing studies and status of its ongoing evaluation of the Company’s pipeline.

Mersana Therapeutics, Inc. today announced that patient dosing is underway in the expansion portion of its UPGRADE-A clinical trial of UpRi in combination with carboplatin in platinum-sensitive ovarian cancer.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced the publication of an Environmental, Social, and Governance summary report.

The University of Texas MD Anderson Cancer Center and Federation Bio today announced a strategic collaboration to design and manufacture a complex, synthetic microbial consortium with the goal of expanding the number of cancer patients who respond to immunotherapy.

Daiichi Sankyo (TSE: 4568) today announced that the new dosing regimen for TURALIO® (pexidartinib) is now available in the U.S. for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.

ReCode Therapeutics announced today the appointment of April Loui, MBA, CSSBB, as senior vice president of quality and chemical, manufacturing and controls (CMC) regulatory affairs.

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its fourth-quarter and full-year financial results on Thursday, Feb. 23, 2022.

Integrated DNA Technologies Expands Access, Expedites Turnaround Time, for Minimal Residual Disease (MRD) Solutions for Cancer Research.

Edesa Biotech, Inc. today announced that it has received approval from Health Canada for a Phase 2 clinical study of the company’s EB06 monoclonal antibody candidate as a treatment for vitiligo.